Bardoxolone methyl does not cut heart risk in diabetes patients with CKD

11/11/2013 |

A Dutch study in the New England Journal of Medicine found bardoxolone methyl was not effective in reducing the odds of cardiovascular death or end-stage renal disease in type 2 diabetes patients with stage 4 chronic kidney disease. Examinations were conducted of 2,185 participants at a median follow-up of nine months, and more patients in the intervention arm were either hospitalized for heart failure or had died of the condition than in the placebo group. The study was ended early.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX